R. Griffin

发表

Polyvalent Human Immune Globulin: A Prospective, Open-Label Study Assessing Anti-Hepatitis A Virus (HAV) Antibody Levels, Pharmacokinetics, and Safety in HAV-Seronegative Healthy Subjects

B. Vince, Jeffrey Price, M. Kankam, 2020, Advances in Therapy.

Inhaled alpha1-proteinase inhibitor therapy in patients with cystic fibrosis.

A. Gaggar, S. Donaldson, H. Dorkin, 2016, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

SPARTA clinical trial design: exploring the efficacy and safety of two dose regimens of alpha1-proteinase inhibitor augmentation therapy in alpha1-antitrypsin deficiency.

Sandra Camprubí, S. Sorrells, R. Griffin, 2015, Respiratory medicine.

Safety and Pharmacokinetics of 120 mg/kg versus 60 mg/kg Weekly Intravenous Infusions of Alpha-1 Proteinase Inhibitor in Alpha-1 Antitrypsin Deficiency: A Multicenter, Randomized, Double-Blind, Crossover Study (SPARK)

M. Campos, C. Strange, M. Brantly, 2013, COPD.

Effects of smoking and clinical status on lung function in human immunodeficiency virus (HIV)-seropositive subjects.

W. Seed, R. Mccabe, P. Snashall, 1997, Respiratory medicine.

Randomized Double-Blind Placebo-Controlled Trial of the Corticosteroid-Sparing Effects of Immunoglobulin in Myasthenia Gravis

T. Toomsoo, A. Vaitkus, M. Pulley, 2022, Neurology.

A Multi‑Center, Open‑Label, Single‑Arm Trial to Evaluate the Efficacy, Pharmacokinetics, and Safety and Tolerability of IGSC 20% in Subjects with Primary Immunodeficiency

P. Kralickova, R. Kobbe, J. Douglass, 2022, Journal of clinical immunology.

Pharmacokinetics, Safety, and Tolerability of Subcutaneous Immune Globulin Injection (Human), 10 % Caprylate/Chromatography Purified (GAMUNEX®-C) in Pediatric Patients with Primary Immunodeficiency Disease

J. Church, G. Kleiner, J. Heimall, 2016, Journal of Clinical Immunology.

Myasthenia gravis: Historical achievements and the “golden age” of clinical trials

D. Gelinas, E. Mondou, R. Griffin, 2019, Journal of the Neurological Sciences.

Measles antibody trough levels after treatment with immunoglobulin products and predicted levels assuming lower measles antibody specifications

P. Vandeberg, M. Cruz, R. Griffin, 2018, Transfusion.

A Phase 3 Multicenter, Prospective, Open-Label Efficacy and Safety Study of Immune Globulin (Human) 10% Caprylate/Chromatography Purified in Patients with Myasthenia Gravis Exacerbations

P. van Damme, V. Bril, J. D. De Bleecker, 2019, European Neurology.

Pharmacokinetics, Safety, and Tolerability of Subcutaneous Immune Globulin Injection (Human), 10 % Caprylate/Chromatography Purified (GAMUNEX®-C) in Pediatric Patients with Primary Immunodeficiency Disease

J. Church, G. Kleiner, J. Heimall, 2016, Journal of Clinical Immunology.